Adding Palifosfamide in Extensive-Stage SCLC Did Not Increase Survival

Adding palifosfamide to carboplatin and etoposide failed to improve survival over the latter two agents alone in patients with extensive-stage small-cell lung cancer.

Source: CancerNetwork - June 19, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news